Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-475 with or without atorvastatin in primary dyslipidemia
2004-000775-34Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lapaquistat in primary dyslipidaemia (3 arms), sponsored by Takeda. Primary endpoints: Overall safety and tolerability and Fasting blood lipid profiles. Started Sep 2004; status: completed.
02
Drugs
lapaquistat
03
Conditions
primary dyslipidaemia
Beyond the preview
Go deeper on 2004-000775-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000775-34.